Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

McGill University

Status and phase

Unknown

Phase 2

Conditions

Gastric Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Treatments

Drug: Taxotere, Cisplatin, and 5-FU

Study type

Interventional

Funder types

Other

Identifiers

NCT00763646

116082

McG 0620

Details and patient eligibility

About

The primary purpose of the study is to determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival. Furthermore the investigators will be assessing the side effects of this chemotherapy strategy. Finally the investigators will determine the ability of specialized imaging technology (PET scan) to document and predict the response of the tumor to this chemotherapy.

Standard therapy for patients with your condition usually consists of surgery (removal of the tumor) followed by combination chemotherapy and radiotherapy. More recently, standard options available to patients with cancer of the stomach or lower esophagus have been expanded to include chemotherapy without radiotherapy prior to and following surgery. While it is believed that chemotherapy prior to surgery is a good option for patients with stomach, it is not known what is the optimal chemotherapy regimen to offer patients prior to surgery to improve the likelihood of cure while limiting side-effects to patients.

Enrollment

30 estimated patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histological diagnosis of adenocarcinoma of the stomach, gastroesophageal junction (GEJ), or lower third of the esophagus.
The tumour must be deemed by the team to be potentially resectable. This includes imaging studies (detailed below) to clinically stage the tumour and rule-out the presence of metastatic disease, and includes a preoperative laparoscopic evaluation.
Stage IB (T1N1 only), II, IIIA, IIIB, and IV (T4N1 only)
Life expectancy greater than 3 months
ECOG performance status of 1 or better (i.e. restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work).
Adequate hematologic reserve: Platelet count 100,000/L, WBC 2000/μL
Creatinine clearance 60 ml/min, AST & ALT 2 ULN, Alkaline phosphatase 2.5 ULN, bilirubin ULN

Exclusion criteria

Prior systemic therapy for gastric cancer
Prior docetaxel-containing chemotherapy
Pre-existing medical conditions precluding treatment, including any contraindication for major surgery
Pregnancy or lactating mothers. Women of childbearing age must use contraception during and for 3 months following treatment.
Unable to give informed consent
Patients that are not able to maintain nutrition by oral consumption of food alone must have additional enteral feeding.
Patients with macroscopic disease noted at laparoscopy
ECOG performance status of 2 or higher
Significant hearing impairment, as judged by the need for or use of a hearing aid. If there is any uncertainty regarding the degree of hearing impairment, an audiogram will be done. If the audiogram is grossly normal or shows only minor hearing impairment (i.e. not requiring hearing aid), the patient may be enrolled.
Unwillingness to undergo investigations and/or treatment as outlined on the study